Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Diastolic Shock Index for Predicting Hemodynamic Instability During Continuous Renal Replacement Therapy (DSI-CRRT)

1 de noviembre de 2026 actualizado por: Mahmut Baran Kasisari, Istanbul University - Cerrahpasa

Continuous renal replacement therapy (CRRT) is commonly used in critically ill patients with acute kidney injury. A frequent complication of CRRT is a drop in blood pressure that requires treatment, known as CRRT-associated hemodynamic instability. This complication is linked to higher mortality and poorer kidney recovery.

The diastolic shock index (DSI) is a simple bedside measure calculated by dividing heart rate by diastolic blood pressure. It requires no additional devices, blood tests or invasive procedures, and higher values have been associated with vasopressor need and mortality in septic shock.

This prospective observational study aims to determine whether DSI measured before the start of CRRT can predict hemodynamic instability during CRRT in adult intensive care unit patients. The predictive performance of DSI will also be compared with the classic shock index, the modified shock index and mean arterial pressure. All data will be obtained from routine clinical monitoring; no additional intervention will be performed for the study.

Descripción general del estudio

Descripción detallada

Background: CRRT-associated hemodynamic instability (CRRT-HI) complicates 19-43% of CRRT sessions and is independently associated with increased mortality and impaired renal recovery. The diastolic shock index (DSI = heart rate / diastolic arterial pressure) reflects both vascular tone (diastolic pressure) and neurohumoral compensation (heart rate) and has been proposed as an early marker of vasoplegia. Its predictive value for CRRT-HI has not been prospectively evaluated.

Objective: To evaluate the diagnostic performance of pre-CRRT bedside DSI in predicting CRRT-HI in critically ill adults.

Design and setting: Prospective observational cohort study conducted in the general intensive care units of Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey. Approximately 70 adult patients (≥18 years) starting CRRT for acute kidney injury will be enrolled.

Definition of CRRT-HI: An event meeting at least one of the following criteria: mean arterial pressure below 65 mmHg; initiation of a new vasopressor or an increase of ≥20% in the norepinephrine dose; crystalloid fluid bolus exceeding 250 mL; or reduction or discontinuation of ultrafiltration.

Data collection: Demographic and clinical characteristics (APACHE II, SOFA-2, comorbidities, CRRT indication and AKI stage), CRRT settings (modality, blood flow, dialysate and replacement fluid rates, ultrafiltration rate, anticoagulation), and baseline laboratory parameters (arterial blood gas, lactate, complete blood count, renal and liver function tests, electrolytes, CRP, procalcitonin) will be recorded. Heart rate, systolic, diastolic and mean arterial pressures, vasopressor/inotrope use and doses will be recorded at CRRT initiation (T0) and at 15, 30, 60 and 180 minutes. DSI, the classic shock index (HR/SAP) and the modified shock index (HR/MAP) will be calculated from these routine monitoring data. No additional blood sampling, tests or invasive procedures will be performed for the study.

Statistical analysis: The predictive performance of DSI, the classic shock index, the modified shock index and mean arterial pressure will be assessed by ROC curve analysis and compared using the DeLong test. Optimal cut-off values will be determined by the Youden index, with corresponding sensitivity and specificity. Independent risk factors for CRRT-HI will be identified by multivariable logistic regression. Associations of DSI and CRRT-HI with 28-day mortality, ICU and hospital length of stay, duration of mechanical ventilation and renal recovery will be evaluated as secondary analyses.

Sample size: Assuming a CRRT-HI incidence of approximately 50% and an expected AUC of 0.75 for DSI, at least 60 patients are required (α = 0.05, power = 80%). Allowing for approximately 15% data loss, 70 patients will be enrolled.

Tipo de estudio

De observación

Inscripción (Estimado)

70

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Consecutive adult patients (≥18 years) admitted to the general intensive care units of Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey, in whom continuous renal replacement therapy is initiated for acute kidney injury.

Descripción

Inclusion Criteria:

  • Age 18 years or older
  • Admission to the general intensive care unit
  • Initiation of continuous renal replacement therapy (CRRT) for acute kidney injury
  • Standard CRRT indication determined by the attending physician (e.g., uremic complications, refractory fluid overload, hyperkalemia, metabolic acidosis)
  • Written informed consent obtained from the patient or legal representative

Exclusion Criteria:

  • Pregnancy
  • Chronic kidney disease on a maintenance intermittent hemodialysis program before the study
  • Significant arrhythmia that may affect diastolic shock index calculation and hemodynamic assessment (e.g., permanent atrial fibrillation, frequent ventricular extrasystoles)
  • Permanent discontinuation of CRRT within the first hour due to technical reasons (e.g., catheter dysfunction, circuit clotting)
  • Missing or inconsistent data on key hemodynamic parameters

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Critically Ill Adults Receiving CRRT

Adult patients (≥18 years) admitted to the general intensive care units of Basaksehir Cam and Sakura City Hospital who are initiated on continuous renal replacement therapy (CRRT) for acute kidney injury. The diastolic shock index (heart rate / diastolic arterial pressure) will be calculated from routine bedside monitoring before and during CRRT, and patients will be followed for the development of CRRT-associated hemodynamic instability. No study-specific intervention will be performed.

Bedside calculation of the diastolic shock index (heart rate / diastolic arterial pressure) from routine hemodynamic monitoring at CRRT initiation and at 15, 30, 60 and 180 minutes. No additional procedure is performed.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Diagnostic Performance of Pre-CRRT Diastolic Shock Index for Predicting CRRT-Associated Hemodynamic Instability
Periodo de tiempo: From CRRT initiation to 180 minutes

Area under the receiver operating characteristic curve (AUC) of the diastolic shock index (heart rate / diastolic arterial pressure) measured immediately before CRRT initiation for predicting CRRT-associated hemodynamic instability. CRRT-associated hemodynamic instability is defined as at least one of the following: mean arterial pressure <65 mmHg; initiation of a new vasopressor or ≥20% increase in norepinephrine dose; crystalloid fluid bolus >250 mL; or reduction or discontinuation of ultrafiltration. The optimal cut-off value will be determined by the Youden index, with corresponding sensitivity and specificity.

From CRRT initiation to 180 minutes

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Comparison of Diastolic Shock Index With Other Bedside Hemodynamic Indices
Periodo de tiempo: From CRRT initiation to 180 minutes

AUC of the diastolic shock index compared with the classic shock index (heart rate / systolic arterial pressure), modified shock index (heart rate / mean arterial pressure) and mean arterial pressure for predicting CRRT-associated hemodynamic instability, compared using the DeLong test.

From CRRT initiation to 180 minutes
Incidence of CRRT-Associated Hemodynamic Instability
Periodo de tiempo: From CRRT initiation to 180 minutes

proportion of patients developing CRRT-associated hemodynamic instability as defined in the primary outcome.

From CRRT initiation to 180 minutes
28-Day All-Cause Mortality
Periodo de tiempo: 28 days after CRRT initiation

All-cause mortality within 28 days of CRRT initiation, compared according to diastolic shock index values and the occurrence of CRRT-associated hemodynamic instability.

28 days after CRRT initiation

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: mahmut baran kaşısarı, md, Başakşehir Çam & Sakura City Hospital

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

15 de noviembre de 2026

Finalización primaria (Estimado)

31 de enero de 2027

Finalización del estudio (Estimado)

1 de febrero de 2027

Fechas de registro del estudio

Enviado por primera vez

1 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

1 de noviembre de 2026

Publicado por primera vez (Actual)

5 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

5 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

1 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir